Recombinant Human Cytochrome P450 2C8 (CYP2C8) Protein (His&Myc)

Name: Recombinant Human Cytochrome P450 2C8 (CYP2C8) Protein (His&Myc)
Brand: Beta LifeScience
SKU: BLC-11058P
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins, Recombinant proteins fall special offers - full-length proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Cytochrome P450 2C8 (CYP2C8) Protein (His&Myc) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	P10632
Target Symbol	CYP2C8
Synonyms	CP2C8_HUMAN; CPC8; CYP2C8; CYPIIC8; Cytochrome P450 2C8; Cytochrome P450 family 2 subfamily C polypeptide 8; Cytochrome P450 form 1; Cytochrome P450 IIC2; Cytochrome P450 MP-12; Cytochrome P450 MP-20; Cytochrome P450 subfamily IIC (mephenytoin 4 hydroxylase) polypeptide 8; Flavoprotein linked monooxygenase; Microsomal monooxygenase; MP 12/MP 20; P450 form 1; P450 IIC2; P450 MP 12/MP 20; S mephenytoin 4 hydroxylase; S-mephenytoin 4-hydroxylase; Xenobiotic monooxygenase
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-10His&C-Myc
Target Protein Sequence	RKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKVYGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRWKEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICSVVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALTRSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTETTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSDLVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFKKSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLPPSYQICFIPV
Expression Range	27-490aa
Protein Length	Full Length of Mature Protein
Mol. Weight	60.1 kDa
Research Area	Cardiovascular
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Primarily catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) with a preference for the last double bond. Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes all trans-retinoic acid toward its 4-hydroxylated form. Displays 16-alpha hydroxylase activity toward estrogen steroid hormones, 17beta-estradiol (E2) and estrone (E1). Plays a role in the oxidative metabolism of xenobiotics. It is the principal enzyme responsible for the metabolism of the anti-cancer drug paclitaxel (taxol).
Subcellular Location	Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein.
Protein Families	Cytochrome P450 family
Database References	HGNC: 2622 OMIM: 601129 KEGG: hsa:1558 STRING: 9606.ENSP00000360317 UniGene: PMID: 29908721 The present study confirms the variable distribution of CYP2C8 (2 and 3) and CYP2C9 (2 and 3) allelic polymorphisms among South Indian diabetic populations. PMID: 28686288 We found that SNPs rs7909236 and rs1934953 of the CYP2C8 gene were significantly associated with increased risk of essential hypertension. PMID: 28513222 Clopidogrel increases the exposure to pioglitazone by inhibiting its CYP2C8-mediated biotransformation. PMID: 27260150 Using an integrated pathway-based approach, we identified polymorphisms in ABCC6, ABCB1 and CYP2C8 associated with overall survival. These associations were replicated in a large independent cohort, highlighting the importance of pharmacokinetic genes as prognostic markers in Ewing sarcoma PMID: 27287205 review summarizes glucuronides as CYP2C8 ligands and the active-site structural features of CYP2C8 that allow potential binding to glucuronides PMID: 28653847 Preliminary results demonstrate SNPs in CYP2C8 represent potential genetic markers of coronary heart disease susceptibility. PMID: 28687336 Inhibition of CYP2C8 activity adds to the protective effects of omega-3 LCPUFA on pathological retinal neovascularization and choroidal neovascularization. PMID: 27417579 CYP2C83 carriers had an increased risk of peripheral neuropathy PMID: 27736846 CYP2C8 Variants are associated with Ischemic Stroke. PMID: 27087514 CYP2C83 is a gain-of-function polymorphism for imatinib N-demethylation, which appears to be mainly mediated by CYP2C8 and not CYP3A4 in vitro in human liver microsomes PMID: 26161459 CYP2C8 genetic polymorphisms may influence outcome of taxane therapy in Roma and Hungarian populations. PMID: 26507668 CYP2C8-derived epoxyeicosatrienoic acids prevented TNF-alpha-induced HUVECs apoptosis via inhibition of oxidative stress associated with the Nrf2 signaling. PMID: 26489615 Interaction among CYP2C8, EPHX2, and CYP4A11 Gene Variants Significantly Increases the Risk for Ischemic Stroke. PMID: 25947240 These comprehensive findings could inform for further genotype-phenotype studies on interindividual differences in CYP2C8-mediated drug metabolism PMID: 26427316 Significant gene-sex interaction for CYP2C83 with twofold increase in the relative risk of essential hypertension and a similar tendency for CYP2J27 associated with coronary artery disease without myocardial infarction in Bulgarian males. PMID: 26404779 We did not observe any association of CYP2C82, CYP2C83, CYP2C92 and CYP2C93 with myocardial infarction PMID: 25560582 CYP2C8 polymorphisms affected neither R- nor S-ibuprofen PMID: 26122864 the CYP2C83 allele has no major impact on paclitaxel metabolism in vitro or of paclitaxel-induced neuropathy PMID: 26115084 Single nucleotide polymorphisms of CYP2C8,CYP2E1 and CYP4B1 are associated with susceptibility to gout in ethnic Han males population. PMID: 26252103 Report impact of CYP2C8-HapC allele on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer. PMID: 21702053 The present study shows that elevated EET levels in BC tissues are associated with upregulation of CYP2C8, 2C9, and 2J2, and downregulation of sEH, and are also associated with aggressive cell behavior in BC patients. PMID: 25406731 Results show that CYP2C8 rs17110453 and EPHX2 rs751141 two-locus interaction confers a significantly higher risk for ischemic stroke. PMID: 25839935 The sudy investigates the impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk for repaglinide. PMID: 24623479 Patients with CYP2C82C and EPHX2 404del variants had worse long-term outcomes while those with EPHX2 287Gln, CYP2J27, and CYP2C9 g.816G variants had favorable outcomes. PMID: 25388680 The CYP2C8 gene may be useful in the prevention and treatment of vascular inflammatory diseases. PMID: 25017038 This study suggests that mitochondrially targeted variant 3 CYP2C8 may contribute to oxidative stress in various tissues. PMID: 25160618 one intronic SNP in ABCG1 (rs492338) surpassed the exploratory significance threshold for an association with paclitaxel-induced neuropathy in the Caucasian cohort (p = 0.0008) but not in the non-Caucasian replication group PMID: 24706167 Significant correlations with chemotherapy resistance were observed for CYP2C83 and CYP2C92 polymorphisms in patients with chronic lymphoproliferative diseases. PMID: 24288737 And those of the genes CYP2C8, CYP3A5 and DPYD associated with toxicity. PMID: 24088129 Based on overexpression of human CYP2C8 in mice, CYP2C8 appears to be part of a novel lipid metabolic pathway influencing retinal neovascularization. PMID: 24458713 The increased risk of paclitaxel-induced neuropathy in patients who carry the CYP2C83 variant is replicated in African Americans and whites. PMID: 23413280 We showed that CYP2C83 was associated with lower plasma levels of rosiglitazone and hence a reduced therapeutic response but also a lower risk of developing oedema during treatment with rosiglitazone. PMID: 23426382 CYP2C83 is associated with decreased pioglitazone plasma exposure in vivo and significantly influences the pharmacokinetic magnitude of the gemfibrozil-pioglitazone drug-drug interaction PMID: 22625877 Report impact of CYP2C8 polymorphisms on rosiglitazone pharmacokinetics and drug interactions. PMID: 23307233 The study described polymorphisms of CYP2C8 in Chinese minorities for the first time, showing significant ethnic differences in the distribution of CYP2C8 among the Han, the Uighur, Hui, and Mongolian Chinese populations. PMID: 23336573 The results indicated that AA and AG genotypes of CYP2C8 (rs1934951) might be predictors for multiple myeloma patients at high risk to develop bisphosphonate-related oxteonecrosis of the jaw. PMID: 23171856 significant positive correlation between CYP2C8 rs 1934951 polymorphism and localization of ONJ. Applying PCA to clinical and biochemical factors sharply separates different variables significantly related to pathological process PMID: 22339777 The translation efficiency (protein/mRNA ratio) for CYP2C8 was inversely correlated with the expression of miR-103 and miR-107. PMID: 22723340 Allele frequencies of functionally important CYP2C8 variants in the Czech population are similar to that of other Caucasian populations. PMID: 22313047 CYP2C8 rs11572080, 416G-A and rs10509681, 1196A-G carriers are more likely to achieve complete clinical response to neoadjuvant paclitaxel in the treatment of breast cancer. PMID: 22527101 Co-administration of febuxostat had no effect on rosiglitazone or N-desmethylrosiglitazone pharmacokinetics, suggesting that febuxostat can be given safely with drugs metabolized through CYP2C8. PMID: 22242967 Report impact of population diversity on the distribution of CYP2C8 polymorphisms among Brazilians. PMID: 21173785 The putative binding site of diosmetin coincided with the CYP2C8 substrate binding site. PMID: 21791871 Data suggest that sipoglitazar is metabolized first by UGT to form an unstable acyl glucuronide, and this acyl glucuronide is then deethylated by CYP2C8. PMID: 22028317 CYP2C8 is the dominant enzyme in the biotransformation of montelukast in humans, accounting for about 80% of its metabolism. CYP3A4 only mediates the formation of the minor metabolite M5a/b, and is not important in the elimination of montelukast. PMID: 21838784 The gemfibrozil-repaglinide interaction could be mainly explained by gemfibrozil 1-O-beta-glucuronide concentration-dependent, mechanism-based inhibition of CYP2C8. PMID: 21778352 HRM analysis is a fast, reliable, accurate and cost-effective screening method for gene mutations, even very similar cDNA sequences with 83% identities, compared with CYP2C8 and CYP2C9 PMID: 22027337 In vitro phenotyping indicated that montelukast is an appropriate probe for CYP2C8 inhibition studies. PMID: 21697463 monocytes and macrophages express the epoxygenases CYP2J2 and CYP2C8 PMID: 22028915

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.